Pages that link to "Item:Q8471"

← Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8471)

What links here

Page:  Namespace:  all (Main) Talk User User talk Wikibase.slis.ua.edu Wikibase.slis.ua.edu talk File File talk MediaWiki MediaWiki talk Template Template talk Help Help talk Category Category talk Item Item talk Property Property talk Module Module talk   Invert selection

Filters

Show transclusions | Hide links | Hide redirects

The following pages link to Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8471):

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

• Targeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5) (Q8449) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5) (Q8462) ‎ (← links)
• Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8463) ‎ (← links)
• Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8464) ‎ (← links)
• Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8465) ‎ (← links)
• Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8466) ‎ (← links)
• Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8467) ‎ (← links)
• Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8468) ‎ (← links)
• Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8469) ‎ (← links)
• Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8470) ‎ (← links)
• Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8471) ‎ (← links)
• Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8472) ‎ (← links)
• Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5) (Q8473) ‎ (← links)
• Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8474) ‎ (← links)
• Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8475) ‎ (← links)
• Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8476) ‎ (← links)
• Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8477) ‎ (← links)
• Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8478) ‎ (← links)
• Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8479) ‎ (← links)
• Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8480) ‎ (← links)
• Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8481) ‎ (← links)
• Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8482) ‎ (← links)
• Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8483) ‎ (← links)
• Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8484) ‎ (← links)
• Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8485) ‎ (← links)
• Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8486) ‎ (← links)
• Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8487) ‎ (← links)
• Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8488) ‎ (← links)
• Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5) (Q8489) ‎ (← links)
• Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5) (Q8490) ‎ (← links)
• Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5) (Q8491) ‎ (← links)
• Competing interests (from DOI: 10.1038/s41392-020-0110-5) (Q8492) ‎ (← links)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)